Seres Therapeutics Inc., of Cambridge, Mass., priced a $133.7 million IPO. The microbiome-focused company plans to sell about 7.4 million shares at $18 each to support development of SER-109 for the prevention of further recurrences of Clostridium difficile infection, as well as work on other drug candidates.